Efficacy of nintedanib as a host-directed therapy candidate in the treatment of tuberculosis
In vitro activity of nintedanib against drug-susceptible and -resistant M. tuberculosis and efficacy in murine infections warrant the continued clinical evaluation of nintedanib as a new adjuvant therapy for standard treatment of TB.
Authors
- Bin Wang (ORCID: https://orcid.org/0000-0001-7104-4543)
- Xueting Qi
- Lei Fu (ORCID: https://orcid.org/0000-0001-7079-4107)
- Xinda Li
- Xi Chen (ORCID: https://orcid.org/0000-0002-3160-614X)
- Yu Lu
- Xiaoyou Chen
- Xiaoyi Luo
Institutions
- Capital Medical University (CN)
- Beijing Chest Hospital (CN)
- Beijing Ditan Hospital (CN)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1093/jac/dkae429
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Beijing Municipal Administration of Hospitals